David Heuzé
Head of Corporate & Financial Communications and ESG

Hello, everyone. Thank you for joining MedinCell's Annual Results Call for the fiscal year ended March 31, 2026. Our press release and presentation are available on our website. Before we start, I invite you to refer to Slide 2 for important information regarding forward-looking statements. Joining me today are Christophe Douat, our CEO. Hi, Christophe.

Christophe Douat
CEO & Director

Hello, everyone.

David Heuzé
Head of Corporate & Financial Communications and ESG

And Stephane Postic, our CFO. Hi, Stephane.

Stephane Postic
Chief Financial Officer

Hello, everyone.

David Heuzé
Head of Corporate & Financial Communications and ESG

And with that, I can now leave the floor to you, Christophe, to start the presentation. Christophe?

Christophe Douat
CEO & Director

Thank you, David. Let me start with MedinCell's trajectory. Our shift to growth strategy is built around 3 engines of growth, all powered by MedinCell's innovation. The first is risperidone LAI with UZEDY successfully marketed in the U.S. since 2023 by our partner, Teva. The second is olanzapine LAI and the third is AbbVie #1, together with our broader pipeline and innovation platform.

What is important here is that these are not isolated assets. There are 3 complementary engines supporting both near-term execution and long-term value creation. As you may recall, 1 year ago, when I introduced our